MADRIGAL PHARMACEUTICALS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428
Mailing Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428
Phone
404-380-9263
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$754.38M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 10-K Annual financial report | February 19, 2026 | View on SEC |
Annual Reports
10-K
February 19, 2026
- FDA granted accelerated approval to Rezdiffra™, the first and only therapy for NASH with liver fibrosis.
- Madrigal transitioned from an R&D-focused company to a commercial one with the launch of Rezdiffra™.
Insider Trading
STRONG SELL
6 insiders
100 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.